SMMT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SM

Mkt Cap

$11.68B

Volume

3.79M

Next Earnings

October 19th

Loading chart

SM

SMMTSummit Therapeutics Inc. Common Stock

SMMT

Pay with—

Available Balance0.00

SM

Mkt Cap

$11.67B

Volume

3.79M

Next Earnings

October 19th

Chart Financials Earnings News About Insider Filings

SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway CombosSummit Therapeutics announced a clinical collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab in combination with Datroway across multiple solid tumors, starting with a phase III study in first-line triple-negative breast cancer. This partnership builds on AstraZeneca's $2 billion investment in Summit announced the previous week, expanding ivonescimab's development pipeline and creating additional clinical and commercial opportunities.Zacks Investment Research · Oct 5, 2026

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer StudySummit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.Zacks Investment Research · Aug 27, 2026

Oil Jumps On Iran Strikes, Nasdaq 100 Falls On Hot Inflation: Stock Market TodayU.S. stocks fell broadly on Wednesday as inflation surged to 4.2% year-over-year and renewed U.S.-Iran tensions in the Strait of Hormuz drove oil prices up 3.3%. Technology stocks led losses amid valuation concerns, while energy stocks rallied. The Nasdaq 100 dropped 1.4%, the S&P 500 fell 0.9%, and the Dow declined 1.2%. Fed rate-hike odds increased following the inflation data.Benzinga · Jun 10, 2026

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock RallySuperstring Capital Management established a new $5.82 million position in Vir Biotechnology by acquiring 730,548 shares in Q1 2026. The investment appears to be a bet on upcoming clinical catalysts rather than current financials, with Vir expecting Phase 3 hepatitis delta data in Q4 2026 and pivotal Phase 3 oncology trials in 2027. Despite being unprofitable, the company has a strong balance sheet with $809.3 million in cash and runway into late 2028.The Motley Fool · May 23, 2026

Roblox, Spotify, And Robinhood Are Among Top 10 Large-Cap Losers Last Week (April 27-May 1): Are The Others In Your Portfolio?Multiple large-cap stocks experienced significant declines last week due to earnings misses and disappointing guidance. The top losers included Rambus (down 28.47%), Summit Therapeutics (down 27.82%), and Teradyne (down 17.85%), with notable declines also from Roblox, Spotify, and Robinhood. Weak financial results and lowered forward guidance across tech, fintech, and other sectors shook investor confidence.Benzinga · May 3, 2026

Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EUU.S. equities reached all-time highs on Friday as Apple's blowout Q2 earnings powered a broad technology rally. The S&P 500 advanced 0.7% to 7,262, while the Nasdaq 100 rose 1.1% to 27,743. Apple surged 5.1% on strong revenue and guidance, while software stocks like Atlassian, Twilio, and Reddit soared on earnings beats. Energy stocks declined as crude oil fell over 3%. Some mega-cap earnings disappointed, including Amgen and Roblox, which posted significant declines.Benzinga · May 1, 2026

IonQ, Oklo, And Robinhood Are Among the Top 10 Large-Cap Gainers Last Week (April 13-April 17): Are the Others in Your Portfolio?A wave of momentum swept through large-cap stocks during the week of April 13-17, 2026, with ten standout performers. Notable gainers include Avis Budget Group (71.48% jump driven by short squeeze), IonQ (62.86% surge following DARPA contract award), Oklo (33.35% rise on nuclear power narrative), Robinhood (33.22% gain from bullish analyst outlook and crypto rebound), and Strategy Inc (31.86% increase). Other top performers include Tempus AI, Credo Technology, Affirm Holdings, and Summit Therapeutics, with gains ranging from 28-31%.Benzinga · Apr 19, 2026

Wall Street Hits New Records, Oil Surges On Hormuz Toll Drama: What's Moving Markets Thursday?U.S. equities reached all-time highs on Thursday as President Trump announced a 10-day ceasefire between Israeli and Lebanese leaders. The S&P 500 advanced to 7,038.57 (+0.2%), while the Nasdaq 100 rallied 0.6% to 26,359 on its 12th straight session of gains. Oil prices surged on Iran's Hormuz toll legislation, with WTI crude jumping 2.5% to $93.58. Energy and technology sectors led gains, though healthcare stocks declined following weak guidance from Abbott Laboratories.Benzinga · Apr 16, 2026

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From NowSummit Therapeutics faces significant near-term risk as its FDA decision on ivonescimab is expected by November 14, 2026. The drug failed to demonstrate statistically significant overall survival improvement in non-Chinese patient populations, which the FDA requires for approval. Meanwhile, Axsome Therapeutics and Madrigal Pharmaceuticals are positioned to potentially outperform Summit by year-end, driven by upcoming catalysts and strong revenue growth.The Motley Fool · Mar 25, 2026

FDA Accepts Summit's Lung Cancer Drug Application, Review UnderwayThe FDA has accepted Summit Therapeutics' Biologics License Application for ivonescimab in combination with chemotherapy for EGFR-mutated non-small cell lung cancer patients. The drug will undergo complete review with a PDUFA goal action date of November 14, 2026. Phase 3 trial data showed ivonescimab demonstrated improved overall survival compared to chemotherapy alone, and the company is expanding its clinical development program with additional Phase 3 studies.Benzinga · Jan 29, 2026

to start trading

SM

SMMTSummit Therapeutics Inc. Common Stock

SMMT

Pay with—

Available Balance0.00

Your PositionYou don't own any SMMT yet.

Related Tickers

Earnings